| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
780 |
681 |
$847K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,024 |
963 |
$558K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,031 |
1,966 |
$231K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
285 |
272 |
$29K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
679 |
529 |
$27K |
| 71045 |
Radiologic examination, chest; single view |
615 |
534 |
$25K |
| 80053 |
Comprehensive metabolic panel |
2,770 |
2,480 |
$22K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,113 |
2,727 |
$17K |
| 84443 |
Thyroid stimulating hormone (TSH) |
532 |
507 |
$9K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
150 |
146 |
$8K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
226 |
216 |
$7K |
| 80061 |
Lipid panel |
591 |
567 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
74 |
70 |
$6K |
| 87428 |
|
99 |
97 |
$5K |
| 83735 |
|
802 |
735 |
$4K |
| 87430 |
|
185 |
180 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
38 |
38 |
$3K |
| 84484 |
|
431 |
312 |
$3K |
| 84439 |
|
256 |
246 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
60 |
60 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
179 |
165 |
$1K |
| 81001 |
|
638 |
580 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
13 |
$997.15 |
| 87420 |
|
12 |
12 |
$889.39 |
| 70450 |
Computed tomography, head or brain; without contrast material |
14 |
13 |
$542.06 |
| 86803 |
|
31 |
30 |
$507.17 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
108 |
99 |
$499.10 |
| 36415 |
Collection of venous blood by venipuncture |
3,146 |
2,671 |
$452.63 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
30 |
25 |
$376.50 |
| 83880 |
|
39 |
39 |
$366.42 |
| 85610 |
|
126 |
116 |
$197.75 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
60 |
45 |
$192.15 |
| 81003 |
|
104 |
94 |
$147.31 |
| 85730 |
|
59 |
57 |
$110.95 |
| 83605 |
|
14 |
12 |
$107.05 |
| 84703 |
|
12 |
12 |
$103.02 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
33 |
27 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
26 |
25 |
$0.00 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
167 |
137 |
$0.00 |